Local failure patterns after radical resection and adjuvant chemotherapy in patients with pN2 nonsmall-cell lung cancer: A retrospective analysis

被引:3
|
作者
Wang, Chenyu [1 ]
Li, Haixia [1 ]
Chen, Yongshun [2 ]
Ge, Hong [1 ]
机构
[1] Zhengzhou Univ, Affiliated Canc Hosp, Dept Radiat Oncol, Zhengzhou, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Peoples R China
关键词
Nodal recurrence; nonsmall cell lung cancer; pN2; postoperative radiotherapy; VINORELBINE PLUS CISPLATIN; POSTOPERATIVE RADIOTHERAPY; TARGET VOLUME; STAGE-I; THERAPY; SURVIVAL;
D O I
10.4103/ijc.IJC_691_18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The patterns of local failure in stage pN2 nonsmall-cell lung cancer (NSCLC) patients undergoing radical resection and adjuvant chemotherapy are controversial. Methods: The sites of local failure were compared in subgroups of patients with relevant clinicopathologic features (e.g., location and size of primary lesions). Results: Totally 75 patients with local failure after radical resection and adjuvant chemotherapy for pN2 NSCLC were included in the analysis. Thirty-seven (49.3%) patients had distant metastasis. The median duration from surgical resection to local failure was 11 months (range: 3-45 months). Sites with >= 10% failure rate in all subgroups based on the location of the primary lesions included 4R, 7, the ipsilateral hilum, and the stump. Additional sites with >= 10% failure rate included 2R, 2L, 4L, and 5 for lesions in the left upper lobe; 4L and 5 for lesions in the left lower lobe; and 2R and 3P for lesions in the right upper-middle lobe. Squamous cell carcinoma affected the stump failure rate compared to adenocarcinoma (56.3% vs. 18.0%, P = 0.003). Tumor diameter >= 5 cm affected the stump failure rate compared to tumor diameter < 5 cm (44.0% vs. 18.0%, P = 0.016). Skip N2 metastasis affected the ipsilateral hilum failure rate compared to nonskip N2 metastasis (7.5% vs. 31.4%, P = 0.008) Conclusions: For pN2 NSCLC patients undergoing radical resection and adjuvant chemotherapy, different lung lobes had different high-risk failure sites. Left lung cancer is prone to bilateral mediastinal lymph nodes recurrence, while right lung cancer mainly recurs with ipsilateral mediastinal lymph nodes. Moreover, the local failure patterns are influenced by pathological type, tumor size, and skip N2 metastasis.
引用
收藏
页码:323 / 329
页数:7
相关论文
共 50 条
  • [1] Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy
    Spaggiari, Lorenzo
    Casiraghi, Monica
    Guarize, Juliana
    Brambilla, Daniela
    Petrella, Francesco
    Maisonneuve, Patrick
    De Marinis, Filippo
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2016, 28 (02) : 593 - 602
  • [2] Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection
    Sugimura, Hiroshi
    Nichols, Francis C.
    Yang, Ping
    Allen, Mark S.
    Cassivi, Stephen D.
    Deschamps, Claude
    Williams, Brent A.
    Pairolero, Peter C.
    ANNALS OF THORACIC SURGERY, 2007, 83 (02): : 409 - 418
  • [3] Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
    Mohamed, S.
    Yasufuku, K.
    Nakajima, T.
    Hiroshima, K.
    Chiyo, M.
    Yoshida, S.
    Suzuki, M.
    Sekine, Y.
    Shibuya, K.
    Agamy, G.
    El-Shahhat, H.
    Fujisawa, T.
    Yoshino, I.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (01) : 127 - 133
  • [4] Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer
    Paesmans, M
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (04) : 389 - 393
  • [5] Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis
    Yang, Chengxi
    Feng, Wen
    Wu, Di
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (01) : 159 - 162
  • [6] Prognostic factors after complete resection of pN2 non-small cell lung cancer
    Sonobe, Makoto
    Date, Hiroshi
    Wada, Hiromi
    Okubo, Kenichi
    Hamakawa, Hiroshi
    Teramukai, Satoshi
    Matsumura, Akihide
    Nakagawa, Tatuo
    Sumitomo, Shin-ichi
    Miyamoto, Yoshihiro
    Okumura, Norihito
    Takeo, Sadanori
    Kawakami, Kenzo
    Aoki, Minoru
    Kosaka, Shinji
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 146 (04): : 788 - 795
  • [7] Adjuvant mediastinal radiotherapy for non-small-cell lung cancer (pN2)
    Gkika, E.
    Schimek-Jasch, T.
    Hoffmann, H.
    ONKOLOGIE, 2022, 28 (12): : 1065 - 1070
  • [9] Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer
    Zhai, Xiaoyu
    Yang, Lu
    Chen, Sipeng
    Zheng, Qiwen
    Wang, Ziping
    CANCER MEDICINE, 2016, 5 (09): : 2286 - 2293
  • [10] Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach
    Rotolo, F.
    Dunant, A.
    Le Chevalier, T.
    Pignon, J. -P.
    Arriagada, R.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2162 - 2166